Capecitabine

Administered via p.o.

HepG2, LS174T WT and LS174T-c2 cells

Capecitabine is currently under investigation in Phase II clinical trials in patients with Breast Cancer Metastasis.

Capecitabine is a tumor-selective fluoropyrimidine carbamate which achieves higher intratumoral 5-FU level with lower toxicity than 5-FU.

Capecitabine is a tumor-selective fluoropyrimidine carbamate.

Both LS174T WT and LS174T-c2 cells show significantly greater sensitivity to Capecitabine when cultivated in the same plates as HepG2 hepatoma with IC50 values of 890 and 630 uM in LS174T WT alone and cultivated with HepG2, respectively. In addition, for the LS174T-C2 subline, the IC50 falls from 330 +/- 4 down to 89 +/- 6 um when cultivated in the same plates as hepatoma cells. Furthermore, Capecitabine induces apoptosis in a Fas-dependent manner, and shows a 7-fold higher cytotoxicity and markedly stronger apoptotic potential in thymidine phosphorylase (TP)-transfected LS174T-c2 cells. [1]

72 hours

359, 35

Data independently produced by, , , Dr. Helen Sadik, of Johns Hopkins University, Capecitabine (Xeloda)purchased from Selleck, Cells were seeded in 96 well paltes, and then treated with the indicated concentration of Capecitabine for 48 h. Cell survival was measured by a standarad MTT assay.

2 years -20CPowder, 2 weeks4Cin DMSO, 2 months-80Cin DMSO